The Food and Drug Administration has shown increased flexibility in regulatory decisions since Kyle Diamantas became acting commissioner, according to observations shared on June 18. Recent developments include uniQure announcing that the FDA will now accept a regulatory filing for its Huntington’s disease gene therapy based on three-year data from its Phase 1/2 trial, reversing a previous refusal.
Other companies have reported similar experiences. Disc Medicine revealed that the FDA agreed its current Phase 3 trial could support another regulatory filing for bitopertin after an earlier rejection. Sanofi announced approval of its type 1 diabetes drug Tzield following a request to revoke the Commissioner’s National Priority Voucher associated with the application. Replimune said it would resubmit its cancer immunotherapy after what CEO Sushil Patel described as “collaborative dialogue” with the agency.
Analysts have connected these shifts to recent leadership changes at the FDA, including the departure of former Commissioner Marty Makary and other key officials. William Blair noted in a statement that, “the current FDA, largely in caretaker mode, appears to be more flexible on regulatory paths for applications where concerns were previously raised.”
Industry stakeholders have responded positively to Diamantas’ approach. Scott Faber, senior vice president of the Environmental Working Group, said Diamantas has “earned the respect of career staff and the FDA stakeholder community.” Steven Grossman, president of policy and regulatory consulting firm HPS Group, predicted that Diamantas may be more inclined to follow traditional decision-making processes and listen closely to expert staff.
However, some analysts caution that this period of stability may be temporary due to legal limits on how long an acting official can serve under the Federal Vacancies Reform Act. Questions remain about whether future permanent commissioners might reverse recent decisions made during this interim period.
Biotech companies such as Biohaven and Capricor Therapeutics have experienced abrupt course reversals from the agency in recent years. Holly Fernandez Lynch from the University of Pennsylvania School of Medicine said biotech firms need consistent guidance: “If they’re making business decisions based on what FDA said, they need to be able to rely on that from administration to administration.”
